A recent Food and Drug Administration report identifies a number of areas where the FDA could improve its combination product review process, according to a Bloomberg BNA article. Combination products – which are made up of combinations of a drug, device and/or bioglogical product – don’t fit in the traditional categories of drugs.

Buchanan FDA Shareholder William A. Garvin was quoted in the article, and told the publication that the report is a “good start” for the FDA. “Hopefully, the fact that Dr. Califf is involved with announcing these actions will ensure that if he becomes Commissioner, he will continue to make resolution of the combination products review issue a high priority,” Garvin said. 

Read the full article – “FDA’s Combo Products Report Good First Step, Lawyers Say” (Bloomberg BNA, October 19, 2015) Subscription required.